MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Abeta42. It binds to and eliminates circulating Abeta peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimers disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted
